Rosetta Radiology Adapts CyberKnife Radiosurgery at its Facility

Manhattan-based Rosetta Radiology declared that it has partnered with Flushing Radiation Oncology to better implement the innovative CyberKnife radiosurgery system to its patients. It will stand out as NYC’s unique hospital facility to offer this advanced technology.

As a unique robotic stereotactic radiotherapy platform, the CyberKnife Radiosurgery System provides specific, precision-targeted radiation therapy for all kinds of tumors, reducing the need for invasive or other complicated methods. CyberKnife stereotactic radiotherapy is ultra-targeted and the incorporated robotic arm guides the radiation beam, providing access to the tumor virtually.

The advantages and significant features of CyberKnife Radiosurgery System are summarized as follows:

• It enables movement of organs and body parts in such as way as to protect the healthy tissues.
• CyberKnife’s unparalleled image guidance software enables administration of higher doses of radiation and more efficiently targets the tumor.
• Compared to conventional external beam radiation therapy, this innovative system is simple and ensures rapid treatment.
• Cyberknife is ideal for treatment of early primary lung cancers demonstrating increased curing rates.
• CyberKnife’s real time tracking ability entails less restrictive immobilization compared to other stereotactic systems.
• It can be used solely or as a boost dose coupled with intensity modulated radiation therapy (IMRT) for treating prostate cancer in men.
• CyberKnife also benefits women with early stage breast cancer subjected to lumpectomy, also enabling them to progress to accelerated partial breast irradiation (APBI).
• CyberKnife can also be used to treat primary and metastatic tumors of the head and neck region, brain, skull base, adrenal glands, spine, liver, kidney, and pancreas.
• It can also enable re-treatment of tumors recurring in areas that were formerly irradiated.